These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30413256)

  • 1. Causal Connections From Chronic Kidney Disease to Cardiac Fibrosis.
    Hulshoff MS; Rath SK; Xu X; Zeisberg M; Zeisberg EM
    Semin Nephrol; 2018 Nov; 38(6):629-636. PubMed ID: 30413256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
    Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
    Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
    Grabner A; Faul C
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
    Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
    J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition.
    de Seigneux S; Martin PY
    Pharmacol Res; 2016 Apr; 106():87-91. PubMed ID: 26900884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
    Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
    Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
    Kang DH
    Contrib Nephrol; 2018; 192():48-55. PubMed ID: 29393109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No apparent link between serum Klotho and phosphate in human chronic kidney disease.
    Hage V; Pelletier S; Fouque D
    Kidney Int; 2016 Jun; 89(6):1399-400. PubMed ID: 27181778
    [No Abstract]   [Full Text] [Related]  

  • 13. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
    Xie J; Wu YL; Huang CL
    Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.
    Adema AY; van Ittersum FJ; Hoenderop JG; de Borst MH; Nanayakkara PW; Ter Wee PM; Heijboer AC; Vervloet MG;
    PLoS One; 2016; 11(1):e0144121. PubMed ID: 26807718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
    Gan L; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 42(9):1058-1065. PubMed ID: 28989152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis.
    Romero-González G; González A; López B; Ravassa S; Díez J
    Nephrol Dial Transplant; 2022 Apr; 37(5):817-824. PubMed ID: 33313766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis.
    Trial J; Heredia CP; Taffet GE; Entman ML; Cieslik KA
    Basic Res Cardiol; 2017 Jul; 112(4):34. PubMed ID: 28478479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of klotho in phosphate metabolism and kidney disease.
    Tan SJ; Smith ER; Hewitson TD; Holt SG; Toussaint ND
    Nephrology (Carlton); 2014 Aug; 19(8):439-49. PubMed ID: 24750549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.